Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease


Authors: M. Meyer, E. Huang, O. Yuzhakov, P. Ramanathan, G. Ciaramella and A. Bukreyev

Journal: Journal of Infectious Diseases

DOI: 10.1093/infdis/jix592

Publication - Abstract

December 21, 2017

Vaccines Nucleic Acid Lipid Nanoparticles mRNA

Abstract

Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.


limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Aug 19, 2021

Microfluidic Formulation of DNA-Loaded Multicomponent Lipid Nanoparticles for Gene Delivery

E. Quagliarini, S. Renzi, L. Digiacomo, F. Giulimondi, B. Sartori, H. Amenitsch, V. Tassinari, L. Masuelli, R. Bei, L. Cui, J. Wang, A. Amici, C. Marchini, D. Pozzi, and G. Caracciolo

DNA Nucleic Acid Lipid Nanoparticles Oncology
With recent successes reflected in literature on mRNA delivery using LNPs, scientists from the University of Rome set out to investigate whether that success can be achieved with plasmid DNA delivery using LNPs (pDNA-LNPs). Authors Quagliarini et al. 2021 synthesized pDNA-LNPs us...
Read More


Publication - Abstract

Feb 15, 2021
Molecular Therapy Nucleic Acids

Selective Suppression of Polyglutamine-expanded Protein by Lipid Nanoparticle-delivered siRNA Targeting CAG Expansions in the Mouse CNS

T. Hirunagi, K. Sahashi, K. Tachikawa, M. Katsuno, et. al.

siRNA Neuroscience Nucleic Acid Lipid Nanoparticles
Polyglutamine (polyQ) diseases are inherited neurodegenerative disorders caused by expansion of cytosine-adenine-guanine (CAG)-trinucleotide repeats in causative genes. These diseases include spinal and bulbar muscular atrophy (SBMA), Huntington’s disease, dentatorubral-pal...
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up